Review Article
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
Table 2
Summary of the double-blind randomized controlled studies comparing celecoxib or etoricoxib with diclofenac. Studies are arranged in chronological order from left to right.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supratherapeutic dose of celecoxib (400 mg BID, double the maximum dose in RA and four times the maximum dose in OA). Data combined for diclofenac- and ibuprofen-treated patients (N = 1985; 800 mg TID). Recommended for patients at higher risk of upper GI clinical events (age > 65 years, history of ulcer or hemorrhage, concurrent use of corticosteroid, anticoagulant, or antiplatelet therapy). OA cohort, etoricoxib 60 mg. In patients taking diclofenac only. NSAIDs, nonsteroidal anti-inflammatory drugs; BID, twice daily; TID, three times daily; OA, osteoarthritis; RA, rheumatoid arthritis; OD, once daily; PPIs, proton pump inhibitors; GI, gastrointestinal; GD, gastroduodenal; AEs, adverse events; Hb, hemoglobin. |